You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

CLINICAL TRIALS PROFILE FOR HYDROGEN PEROXIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for hydrogen peroxide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Development Center for Biotechnology, Taiwan Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Program Office, National Science & Technology, Biotechnology & Pharmaceuticals Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Taipei Veterans General Hospital, Taiwan Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status National Taiwan University Hospital Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for hydrogen peroxide

Condition Name

Condition Name for hydrogen peroxide
Intervention Trials
Tooth Discoloration 6
COVID-19 6
Tooth Sensitivity 4
Covid19 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for hydrogen peroxide
Intervention Trials
Dentin Sensitivity 10
COVID-19 10
Tooth Discoloration 8
Hypersensitivity 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for hydrogen peroxide

Trials by Country

Trials by Country for hydrogen peroxide
Location Trials
United States 50
Brazil 11
Egypt 9
United Kingdom 6
Australia 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for hydrogen peroxide
Location Trials
California 8
Texas 5
Tennessee 4
New York 4
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for hydrogen peroxide

Clinical Trial Phase

Clinical Trial Phase for hydrogen peroxide
Clinical Trial Phase Trials
PHASE4 2
PHASE3 2
PHASE2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for hydrogen peroxide
Clinical Trial Phase Trials
Completed 53
Not yet recruiting 19
Recruiting 17
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for hydrogen peroxide

Sponsor Name

Sponsor Name for hydrogen peroxide
Sponsor Trials
Emphycorp 3
University of Milan 3
Universidade Federal do Para 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for hydrogen peroxide
Sponsor Trials
Other 134
Industry 23
NIH 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Hydrogen Peroxide in Clinical Trials and Market Dynamics: An In-Depth Analysis

Last updated: November 3, 2025


Introduction

Hydrogen peroxide (H₂O₂) is predominantly recognized for its antiseptic properties, employed in wound cleaning, bleaching, and industrial applications. Historically, its use has been largely over-the-counter and industrial, with limited clinical trial activity directed toward new therapeutic applications. This analysis examines recent updates from clinical trials, evaluates the current market landscape, and projects future growth opportunities rooted in emerging clinical and industrial trends.


Clinical Trials Landscape for Hydrogen Peroxide

Current State of Clinical Research

Despite widespread industrial and household applications, hydrogen peroxide has surprisingly limited presence in rigorous clinical research targeting novel therapeutic indications. A review of ClinicalTrials.gov indicates only a handful of active or completed studies, primarily centered on its antiseptic role and dental applications.

  • Antiviral and Antimicrobial Potential: Recent exploratory studies have investigated hydrogen peroxide's efficacy as a sanitizer against emerging viral pathogens, notably SARS-CoV-2, aligning with its known oxidative disinfectant properties. Trials such as NCT04330376 assessed the safety of hydrogen peroxide vapor in hospital settings, emphasizing its potential to reduce nosocomial infections.

  • Oncology and Wound Healing: A sparse subset of trials explores hydrogen peroxide’s role in wound healing and cancer treatment. However, these are mainly early-phase, non-randomized studies focusing on topical applications, with no definitive evidence supporting systemic therapeutic use.

  • Limitations and Challenges: Clinical research hampered by hydrogen peroxide's cytotoxicity at higher concentrations and its potential to cause tissue damage limits its clinical appeal for systemic therapeutic indications. Furthermore, its rapid decomposition complicates sustained delivery in vivo, constraining ongoing studies.

Regulatory and Scientific Barriers

Hydrogen peroxide's status as a relatively simple molecule with widespread over-the-counter availability has resulted in its classification predominantly as a medical device or disinfectant rather than a pharmaceutical agent. Regulatory pathways for novel therapeutic claims are complex, requiring rigorous safety and efficacy data, which are currently scarce for systemic or novel uses.


Market Analysis of Hydrogen Peroxide

Current Market Size

The global hydrogen peroxide market was valued at approximately USD 1.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of around 4.2% from 2023 to 2030[1]. This growth is driven primarily by industrial sectors such as pulp and paper, textile bleaching, and electronics.

  • Applications:
    • Industrial: 70%, including bleaching, wastewater treatment, and chemical manufacturing.
    • Healthcare: 10%, used mainly in disinfectants, sterilants, and wound care.
    • Other Sectors: Cosmetics, food, and environmental sanitation.

Healthcare Segment Outlook

Despite a modest 10% share, the healthcare segment exhibits significant potential driven by increasing demand for disinfectants amid global health concerns, notably post-pandemic sterilization standards.

  • Disinfectant Demand Surge: The COVID-19 pandemic accelerated demand for hydrogen peroxide-based disinfectants, with large-scale procurement by hospitals and sterilization companies.

  • Innovations and Product Development: Companies are exploring stabilized formulations, vaporized hydrogen peroxide sterilizers, and low toxicity topical applications, opening avenues for clinical adoption.

Emerging Trends and Opportunities

While direct therapeutic applications are limited, several adjacent markets hint at potential growth trajectories:

  • Air and Surface Sanitization: Enhanced use in HVAC systems and portable sterilizers.
  • Medical Device Sterilization: Growing acceptance of hydrogen peroxide vapor (HPV) sterilizers, which utilize hydrogen peroxide gas plasma for terminal sterilization of surgical instruments.

Future Market Projections

Growth Drivers

  • Post-pandemic Hygiene Requisites: Persistent emphasis on infection control boosts demand for hydrogen peroxide disinfectants.
  • Regulatory Endorsements: Approvals of hydrogen peroxide-based sterilizers by bodies like the FDA and EMA reinforce market confidence.
  • Industrial Expansion: Growth in pulp and paper, textiles, and electronics sectors sustains industrial demand.

Constraints and Challenges

  • Clinical Limitations: The narrow pipeline for therapeutic clinical trials diminishes prospects for hydrogen peroxide as a direct drug candidate.
  • Safety Concerns: Potential tissue toxicity limits systemic uses, confining applications mainly to topical and sterilization procedures.
  • Market Competition: Established disinfectants (e.g., alcohol, bleach) and emerging nanomaterials compete with hydrogen peroxide in disinfectant markets.

Projection Summary

By 2030, the total hydrogen peroxide market is anticipated to approach USD 2.2 billion, with healthcare-related applications contributing significantly to this growth. However, the compound annual growth rate in clinical drug development remains subdued, reflecting the molecule's limited direct therapeutic pipeline. Industry applications, especially sterilization and industrial cleaning, will underpin most growth.


Implications for Stakeholders

  • Pharmaceutical Developers: Focus on formulation innovations—stabilized hydrogen peroxide derivatives and delivery systems—to unlock therapeutic potentials.
  • Investors: The disinfectant segment offers robust near-term returns, particularly in sterilization markets.
  • Regulators: Emphasize safety data and standardized protocols for hydrogen peroxide-based sterilization devices to facilitate broader acceptance.
  • Researchers: Emphasize safety and efficacy studies for niche therapeutic uses, balancing oxidative benefits and cytotoxic risks.

Key Takeaways

  • Clinical trials seeking novel therapeutic uses for hydrogen peroxide are scarce, primarily confined to disinfectant and sterilization applications, with limited therapeutic indications explored.
  • The hydrogen peroxide market is predominantly driven by industrial applications, but healthcare demand—particularly for high-grade sterilization—is expanding robustly.
  • Technological advances in sterilization equipment and increased hygiene awareness underpin future growth, though systemic drug development prospects remain limited.
  • Safety concerns and regulatory hurdles restrict hydrogen peroxide’s transition from disinfectant to therapeutic drug, favoring its use in topical and sterilization settings.
  • Stakeholders should prioritize innovations in formulation and delivery systems, aligning with regulatory standards, to unlock the molecule’s full commercial potential.

FAQs

1. What are the main therapeutic applications under clinical investigation for hydrogen peroxide?
Current research primarily focuses on its use as a surface disinfectant and sterilization agent, with minimal clinical trials exploring systemic or therapeutic indications due to safety concerns.

2. How does hydrogen peroxide compare to other disinfectants in the healthcare sector?
Hydrogen peroxide offers advantages like broad-spectrum antimicrobial activity, low residual toxicity, and eco-friendliness, making it suitable for sterilization, but its limited stability and toxicity at high concentrations present challenges against competitors like alcohol and bleach.

3. Are there any ongoing clinical trials exploring hydrogen peroxide as a drug?
Few trials are underway, mainly assessing its vapor form for environmental disinfection. No substantial clinical research is focusing on systemic therapeutic uses at this time.

4. What are the regulatory hurdles for expanding hydrogen peroxide’s therapeutic applications?
Rigorous safety and efficacy data are necessary, along with standardized formulations. Its cytotoxicity at higher concentrations hinders approval for systemic use, confining applications mainly to topical and sterilization devices.

5. What future innovations could boost hydrogen peroxide’s market growth?
Development of stabilized, targeted delivery systems; advanced sterilization technologies; and safe topical formulations could expand its clinical and industrial applications.


References

  1. Grand View Research, Inc. "Hydrogen Peroxide Market Size, Share & Trends Analysis Report," 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.